Pfizer Inc. (NYSE:PFE) Shares Bought by Oak Harbor Wealth Partners LLC

Oak Harbor Wealth Partners LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 3.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 73,828 shares of the biopharmaceutical company’s stock after purchasing an additional 2,375 shares during the quarter. Oak Harbor Wealth Partners LLC’s holdings in Pfizer were worth $2,137,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of PFE. Massachusetts Financial Services Co. MA raised its holdings in shares of Pfizer by 3.2% during the second quarter. Massachusetts Financial Services Co. MA now owns 71,794,056 shares of the biopharmaceutical company’s stock worth $2,008,798,000 after purchasing an additional 2,241,609 shares during the period. Van ECK Associates Corp boosted its stake in shares of Pfizer by 2.8% during the 3rd quarter. Van ECK Associates Corp now owns 16,560,256 shares of the biopharmaceutical company’s stock worth $477,929,000 after acquiring an additional 456,168 shares in the last quarter. Diamond Hill Capital Management Inc. lifted its holdings in shares of Pfizer by 4.1% in the third quarter. Diamond Hill Capital Management Inc. now owns 16,553,997 shares of the biopharmaceutical company’s stock valued at $479,073,000 after purchasing an additional 658,420 shares in the last quarter. Federated Hermes Inc. raised its holdings in shares of Pfizer by 3.3% during the second quarter. Federated Hermes Inc. now owns 14,923,545 shares of the biopharmaceutical company’s stock worth $417,561,000 after acquiring an additional 470,003 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Pfizer by 4.3% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 13,118,764 shares of the biopharmaceutical company’s stock worth $379,657,000 after acquiring an additional 544,418 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PFE has been the topic of a number of recent research reports. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Citigroup began coverage on shares of Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price on the stock. Eight equities research analysts have rated the stock with a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Stock Down 2.6 %

NYSE:PFE opened at $26.02 on Friday. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The company has a 50-day moving average of $28.76 and a 200 day moving average of $28.67. The firm has a market cap of $147.46 billion, a PE ratio of 35.16, a price-to-earnings-growth ratio of 0.85 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same period last year, the firm posted ($0.17) EPS. Pfizer’s revenue was up 31.2% on a year-over-year basis. As a group, research analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.46%. Pfizer’s dividend payout ratio is presently 227.03%.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.